Blood-based cancer early detection tests are advancing quickly but how should we interpret performance data? Join BLOODPAC at #AACR26 for a session exploring single- and multi-cancer detection test performance, real-world prevalence, and implications for clinical adoption. 🗓️ Apr 18 | 2:30–4 PM

We are pleased to welcome @eortc.org as BLOODPAC’s newest member. EORTC is an international, nonprofit cancer research organization coordinating clinical and translational studies to help improve patient outcomes worldwide. #BLOODPAC #CancerResearch

And just like that, BLOODPAC’s Q1 2026 meeting is in the books. From working group milestones to big-picture strategy, the collaboration over these two days shows why this community matters. Thank you to Guardant Health for hosting us in San Diego. On to Q3! 🚀

Celebrating the publication of the “Generic Protocols for Analytical Validation of Tumor-Informed ctDNA Assays for MRD: The BLOODPAC MRD AV Working Group Consensus Recommendation” in JCO PO and now advancing tumor-agnostic protocols. Great in-person progress on the next manuscript. #BLOODPAC #MRD

Expanding our MRD work to focus on clinical utility. At this workshop, co-chairs and members refined the goals and scope for a potential new working group. Strong engagement and great momentum for this next phase. #BLOODPAC #MRD #ClinicalUtility

We’ve launched a new diffuse large B-cell lymphoma #DLBCL Working Group!🙌 The kickoff brought together members and prospective members to discuss the focus and proposal for the group. Excited to expand into this space and get started.

A “double feature” at Q1: the Accessibility Working Group is advancing two initiatives; a peer-reviewed publication on assay-specific blood collection kits and a project exploring how clinicians perceive and use liquid biopsy. Focused on improving access from collection to care.

Day 1 of our Q1 meeting featured an update from the Reimbursement Working Group on their upcoming paper addressing Financial Toxicity in precision oncology. The goal: reduce barriers to medical necessity & improve coverage pathways while maintaining quality & expanding patient access.

At our Q1 meeting, the team rolled up their sleeves to discuss key parameters for the clinical study they’re developing, from patients to analytical partners and other critical elements of the study design. These discussions are helping lay the foundation as planning moves forward.

Productive workshop from our Early Detection & Screening Working Group at the Q1 meeting! Co-chairs Tina Clarke (GRAIL) and Bree Mitchell (Natera) shared progress as the group expands into clinical validation of early detection tests and prepares for a 2026 AACR session.

Thank you to @guardanthealth.bsky.social for hosting our Q1 meeting! Darya Chudova, Guardant's CTO & BLOODPAC's Scientific co-chair welcomed members and reminded us that BLOODPAC’s mission remains the same: reducing the time it takes for liquid biopsies to impact patient care.

Great Q1 meeting for the Multi-Omics WG at @guardanthealth.bsky.social! The team refined key lexicon terms and, after strong progress this past year, is now launching two subgroups: Pre-Analytic/Lab and Data/AI. Momentum continues! #BLOODPAC #MultiOmics

Day 2 of BLOODPAC’s Q1 2026 meeting is underway in San Diego!🌊 After a strong start yesterday, we’re diving back in with our members for working group updates, thoughtful discussion, and continued collaboration to advance liquid biopsy science. Thank you again to Guardant Health for hosting us! 🫶

A highlight from the Q1 Day 1 recap: collaboration between BLOODPAC’s Data Science and Global Regulatory Working Groups to explore how our standardization efforts in the U.S. could also support progress in the EU.

During the BLOODPAC Q1 Day 1 recap, the RDE Working Group shared a new project developing Minimum Technical Data Elements (MTDEs) for saliva and buccal samples. An outstanding group of experts is helping shape and accelerate this effort. #BLOODPAC

At the Q1 Day 1 recap, the #CHIP Working Group highlighted the publication of their lexicon, a key step toward greater clarity in the field. They’re now focusing on a new paper to help disambiguate methods for CHIP identification. 👉Lexicon paper: ascpt.onlinelibrary.wiley.com/doi/10.1111/...

BLOODPAC’s Q1 2026 meeting is live in San Diego, CA! We’re excited to gather our members for meaningful collaboration and forward-looking discussions around all things liquid biopsy. Thank you to @guardanthealth.bsky.social for hosting us. Looking forward to a dynamic and productive meeting!

For new members, our quarterly meetings offer immediate value, deep insight, open collaboration, and a strong sense of community. One of the most powerful outcomes is the development of shared tools and best-practice toolkits for the LBx community. Looking forward to our Q1 2026 meeting this week 🙌

🎉 Just 7 days to go! 🎉 BLOODPAC’s first quarter meeting is right around the corner! Join us in just one week on March 4th and 5th in San Diego, California, hosted by @guardanthealth.bsky.social . We’re so excited to see everyone there!

BLOODPAC’s quarterly meetings offer a rare model for collaboration, bringing diverse stakeholders together to develop strong, shared industry recommendations. Members see real value in working collectively to reach patients faster. Looking forward to see all our members at the Q1 2026 meeting.

Welcome Norgen Biotek to the BLOODPAC community! 🎉 Norgen Biotek is a Canadian biotech company offering sample prep and research tools used in life science and molecular diagnostics. 🌍🔬Learn more at norgenbiotek.com.

🎉 The countdown continues! 🎉 Only 14 days left until BLOODPAC’s in-person first quarter meeting! Join us on March 4th and 5th in San Diego, CA, hosted by @guardanthealth.bsky.social. We’re getting closer and can't wait to see everyone there!

BLOODPAC’s quarterly meetings provide invaluable opportunities for networking and industry insight. Members, like David Merriam, value the ability to learn from peers while shaping what comes next in diagnostics. We’re looking forward to our Q1 2026 meeting.

Whether our members are an early-stage company or an established organization, BLOODPAC’s quarterly meetings offer a unique space to collaborate, learn, and help shape the future of diagnostics. Our members say it best—this community makes a difference. Excited for our Q1 2026.

We’re pleased to welcome Insightec as the newest member of BLOODPAC! Insightec is a global healthcare company advancing focused ultrasound medical technologies used in clinical practice worldwide. Learn more at insightec.com.

What makes BLOODPAC’s quarterly meetings special? A truly collaborative environment where industry, researchers, and innovators come together to focus and tackle shared challenges. Our members consistently highlight the value of learning, sharing, and building together. Q1 2026 meeting coming soon!

BLOODPAC was active today at the 10th Liquid Biopsy for Precision Oncology Summit. Our ED Lauren Leiman moderated a panel on bridging innovation to access and led an interactive session on standardization. We highlighted how standardization accelerates validation and patient access.

🎉 Let the countdown begin! 🎉 Just 1 month until BLOODPAC’s in-person first quarter meeting! Join us on March 4th and 5th in San Diego, California, hosted by Guardant Health. We can't wait to see everyone there!

Today our Executive Director joined a panel at the 10th Liquid Biopsy for Precision Oncology Summit, hosted by Personalis, discussing how ultrasensitive MRD testing may help accelerate clinical development and regulatory pathways. 🧬

Tomorrow: BLOODPAC Executive Director Lauren Leiman will speak at Hanson Wade’s Liquid Biopsy for Precision Oncology Summit, presenting on standardization challenges and joining a panel on aligning standards, policy, and reimbursement. lbx-summit.com

BLOODPAC meetings aren’t just about networking—they’re about meaningful collaboration across diagnostics, data science, and regulation. Members value the chance to learn from peers and work toward shared solutions. Can't wait to see all our members at the Q1 2026.

🎉 Welcome to BLOODPAC, @Twist Bioscience! 🧬 Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform. To learn more about Twist Bioscience, visit: 👉 www.twistbioscience.com

BLOODPAC Executive Director Lauren Leiman will participate in Hanson Wade’s 10th Annual Liquid Biopsy for Precision Oncology Summit on Feb 4 in San Diego, presenting on standardization and joining a panel on policy and reimbursement. lbx-summit.com

Mark your calendars! BLOODPAC’s Q1 2026 in-person meeting is coming this March in San Diego, hosted by Guardant Health. We’re looking forward to two days of collaboration, project updates, and driving innovation in liquid biopsy. See you soon!

One of the greatest strengths of BLOODPAC is bringing science, industry, and regulatory perspectives into the same room. Our quarterly meetings foster the kind of collaboration needed to move diagnostics forward responsibly. We can't wait for our 2026 Q1 meeting! 🙌

📣 New from BLOODPAC! Our MRD AV Working Group has published consensus protocols for analytical validation of tumor-informed ctDNA MRD assays—years in the making and announced today via press release. 🔗 Press: www.prnewswire.com/news-release... #MRD #LiquidBiopsy

🚨 New update! The BLOODPAC Dictionary now includes terms from Lexicon for Clonal Hematopoiesis in Liquid Biopsy, our first CH/CHIP Working Group paper. Explore the full paper & dictionary on our website! www.bloodpac.org

Looking back at our Q3 2025 meeting, members like Andrew Anfora shared why BLOODPAC’s quarterly meetings matter—bringing years of collaboration together. We’re excited to carry that momentum into our Q1 2026 meeting.

Exciting news! BLOODPAC’s in-person Q1 2026 meeting is happening this March - hosted by our valued member, @guardanthealth.bsky.social, in San Diego, CA. Join us for two impactful days of collaboration, knowledge sharing, and progress updates on our key initiatives.

🙌 We’re excited to announce Lexicon for #ClonalHematopoiesis in #LiquidBiopsy, the first paper from our CH/CHIP Working Group. This lexicon standardizes terminology to improve communication and consistency in liquid biopsy research and clinical use. 🔗 Read more: bit.ly/BP-CH-lexicon

Looking back on everything we achieved last year. Huge thanks to our amazing team and members. Your hard work drives every milestone. 💙 Take a peek at our 2025 highlights below, and here’s to an even better 2026! ✨

Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem. #BLOODPAC #Biofidelity

How should we measure performance for blood-based early detection? Our Summer Seminar tackled modern metrics, diagnostic yield, and what clinicians/patients actually need. 👉Read the recap: www.bloodpac.org/bloodpac-blo... 👉Watch the recording: www.bloodpac.org/performance-...

We were proud to join #AMP2025! Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology

We’re excited to welcome nRichDX as BLOODPAC’s newest member! Their patented Revolution Sample Prep System™ aims to advance liquid biopsy by maximizing recovery of rare analytes to improve diagnostic accuracy. 🔗 nrichdx.com

Excited to share that BLOODPAC Executive Director, Lauren Leiman, will moderate “Demystifying MRD with BLOODPAC” at #AMP2025 on Nov 12, 4–4:50 PM in Boston! Join experts from Illumina, HMS, BMS & BLOODPAC to explore the future of MRD testing. #LiquidBiopsy #Oncology

Huge thanks to all who joined our 4th Annual BLOODPAC New Frontiers Seminar: “New Frontiers in Therapy Selection: Beyond DNA Mutations.” Inspiring talks & discussions on the future of precision oncology! Highlights coming soon! #LiquidBiopsy #TherapySelection #PrecisionOncology #BLOODPAC

Thank you to ISLB and Dr. Christian Rolfo for an inspiring 7th Annual Congress of Liquid Biopsy! Our Executive Director, Lauren Leiman, joined experts from BLOODPAC member organizations—Thermo Fisher, Guardant, Foundation Medicine/Roche, and Natera—to discuss translation of LBx into the clinic.

📅 It’s almost here! The BLOODPAC New Frontiers Seminar happens this week, November 5, 1–3 PM ET. Join us to explore how multimodal data is transforming therapy selection and advancing personalized cancer care. 🎟️ Register here: bit.ly/BP-New-Front...

We’re bringing together an outstanding lineup for this year’s BLOODPAC New Frontiers Seminar. Don’t miss out on a great discussion on how multimodal data can advance therapy selection. 🗓️ November 5 | 1–3 PM ET 🎟️ Register here: bit.ly/BP-New-Front...